Factor D complement inhibitors companies working in the market are AstraZeneca, Alexion (a subsidiary of AstraZeneca), BioCryst, and others. ALBANY, NY, UNITED STATES, December 4, 2024 /EINPresswire / ...
BioCryst Pharmaceuticals, Inc. proof-of-concept data from a phase 1 study, using BCX10013 for the treatment of patients with complement-mediated disorders, is expected in 2024. Oral C2, C5, and ...
The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). EVH affects ...
For years, Alexion has been the only name in the game for a blood disease called paroxysmal nocturnal hemoglobinuria (PNH). Now, a number of Big Pharmas want in, vying to show their candidates can go ...
Achillion Pharmaceuticals, Inc.ACHN announced positive interim data from clinical studies evaluating its factor D inhibitors - ACH-4471, ACH-5228 and ACH-5548. Two phase II studies are evaluating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback